<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240305</url>
  </required_header>
  <id_info>
    <org_study_id>4522AS/0004</org_study_id>
    <nct_id>NCT00240305</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo Controlled, Crossover Dose-Ranging Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the dose-related effect of treatment with
      rosuvastatin on production and fractional catabolism of apolipoprotein A-I (apoA-I) and
      apolipoprotein A-II (apoA-II), and on the plasma apoA-I, apoA-II and high-density lipoprotein
      cholesterol (HDL-C) concentration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the dose-related effect of treatment with rosuvastatin on production &amp; fractional catabolism of apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), &amp; on the plasma apoA-I, apoA-II &amp; high-density lipoprotein cholesterol (HDL-C) c</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the dose-related effect of treatment with rosuvastatin on cellular cholesterol efflux,total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-LDL-C, triglyceride &amp; pre1-HDL concentrations,HDL2,HDL3 cholesterol ratio</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesteryl ester transfer protein (CETP) and lecithin:cholesterol acyl transferase (LCAT) activity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lathosterol and campesterol, total apolipoprotein B (apoB), nonesterified fatty acids (NEFA) and apolipoprotein C-III (apoC-III) plasma concentrations.</measure>
  </secondary_outcome>
  <enrollment>15</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Dyslipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  male aged 30 to 70 years of age

          -  LDL-C &lt;6 mmol/L

          -  HDL-C ≤1.2 mmol/L

          -  at least 2 of the following:

          -  insulin resistance (fasting glucose &gt;6 mmol/L or insulin &gt;10 mU/L or HOMA score &gt;2.5)

          -  central obesity (waist circumference &gt;=94 cm).

          -  plasma triglycerides &gt;=1.7 and &lt;4.5 mmol/L.

          -  blood pressure &gt;=130/ &gt;=85 mm Hg or on drug treatment for hypertension

        Exclusion Criteria:

          -  LDL cholesterol &gt;=6 mmol/L

          -  pre-existing or history of cardiovascular disease, diabetes, renal dysfunction,
             anaemia, history of significant dyspepsia or gastrointestinal disease

          -  apolipoprotein genotype E2/E2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald F. Watts, BSc PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Department of Medicine, Royal Perth Hospital, University of Western Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2005</study_first_posted>
  <last_update_submitted>March 13, 2009</last_update_submitted>
  <last_update_submitted_qc>March 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2009</last_update_posted>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Dyslipidaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

